FDA staff confirmed Jammu and Kashmir’s finding that the vaccine was 66 percent effective overall in preventing moderate and severe cases of COVID-19.
While not as strong as Pfizer and Modern’s two-dose vaccines, that efficacy rate may still make J&J’s shot a helpful weapon in the fight against the pandemic.
New Jersey officials said the clinical trial of about 44,000 New Jersey-based J & J’s people also did not pose any significant safety concerns, which prevented the FDA from granting emergency use authorization for the vaccine.
The FDA released its analysis of the shot prior to Friday’s meeting of its vaccines and the associated Biological Products Advisory Committee, a panel of experts that would advise whether to vacate J&K vaccines for emergency use.
The FDA granted emergency approval for the Modern and Pfizer vaccines in December following positive recommendations from the advisory panel.
With post wires